An Open-label, Randomized, Single-dose, Parallel Group Study to Assess the Bioequivalence of Romosozumab (AMG 785) Following Subcutaneous Administration of 90 mg/mL Concentration Versus 70 mg/mL Concentration in Healthy Subjects

Sponsor ID

20120277

Clinicaltrials.gov ID

EUCTIS ID

N/A

EudraCT ID

N/A

Study Details

Phase

Phase 1

Product

AMG 785

Type

Interventional

Masking

N/A

Enrollment

N/A

Additional Study Details

Primary Outcome Measures

Not Available

Secondary Outcome Measures

Not Available

Study Synopsis

Available Language(s): English

Location

Status

Location

Research Site

Dallas, TX, United States, 75247

Status

Recruiting